Spotlight
A specially engineered antibody capable of delivering RNA therapies to hard-to-reach, treatment-resistant tumors significantly shrank tumor size and improved survival in animal models, according to a study published July 16 in Science Translational Medicine. The study provides evidence that, once injected into the bloodstream, the antibody TMAB3, combined with a type of RNA that stimulates an innate immune reaction, can localize to tumors and penetrate and destroy stubborn diseased cells in pancreatic, brain, and skin cancers. The research reported in this news article was supported by the National Institutes of Health, the Damon Runyon Cancer Research Foundation; the American Association for Cancer Research; Pew Cancer Research Scholars; Cancer Research Institute-Clinic & Laboratory Integration Program (CLIP); Yale Cancer Center; Blavatnik Fund for Innovation at Yale; Gennao Bio Sponsored Research Grant to Yale; and Yale University.
Struggling and vulnerable families and children are to be given a better start in life after a new government fund was announced today (Monday 14 July), which will provide them with the support and funding needed to access a better education, a safe home, and the caring supportive environment they need to flourish. The Better Futures Fund will support up to 200,000 children and their families over the next ten years by bringing together government, local communities, charities, social enterprises, investors, and philanthropists to work together to give children a brighter future. The launch is backed today by groups including Save the Children UK, The King’s Trust and Oxford University’s Blavatnik School of Government.
Harvard Business School (HBS) has named its 2025-26 Blavatnik Fellows and the program’s twelfth cohort. Launched in 2013, the Blavatnik Fellowship in Life Science Entrepreneurship is part of a gift to Harvard University from the Blavatnik Family Foundation. The Blavatnik Fellowship offers HBS alumni and Harvard-affiliated postdoctoral researchers the opportunity to advance new ventures around promising life science technologies and develop their leadership talents during a 12-month fellowship year.
The Blavatnik Fund for Innovation at Yale is pleased to announce the recipients of its 2025 Accelerator Awards, mid-cycle awards that support generating data for early-stage Yale life science research not typically funded by traditional research grants. This year’s awardees—eight research teams from across Yale—are addressing urgent challenges in cancer, ALS, inflammatory bowel disease, cardiovascular conditions, and rare genetic disorders and include innovative AI driven approaches to deliver faster drug development and better clinical trial outcomes.
Providing many of the world's best researchers, scientists, and universities with support, and funding to discover breakthroughs that solve humankind's greatest challenges.
The Foundation contributes to renowned institutions that showcase the breadth of arts and culture, including performance, exhibition and education.
The Blavatnik Archive is a nonprofit foundation dedicated to preserving and disseminating materials that contribute to the study of 20th-century Jewish and world history, with a special emphasis on World War I, World War II, and Soviet Russia.
